Eli Lilly’s stock surges toward a 5th straight record after an earnings beat and upbeat outlook

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

المملكة العربية السعودية أخبار أخبار

المملكة العربية السعودية أحدث الأخبار,المملكة العربية السعودية عناوين

Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.

Shares of Eli Lilly and Co. LLY, +5.77% rallied toward a fifth-straight record close in premarket trading Tuesday, after the drug maker’s fourth-quarter earnings beat expectations, helped by a 16% jump in prices, and provided an upbeat 2024 revenue outlook. Net income rose to $2.19 billion, or $2.42 a share, from $1.94 billion, or $2.14 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $2.49 beat the FactSet consensus of $2.30. Revenue jumped 28.

95 billion, as prices increased 16%, volume rose 11% and currency translation added 1% growth. Sales of the company’s obesity drug Zepbound total $175.8 million, while there were no recorded sales of Covid-19 antibodies. For 2024, the company expects adjusted EPS of $12.20 to $12.70, which surrounds the current FactSet consensus of $12.39, and expects revenue of $40.4 billion to $41.6 billion, which is above expectations of $39.3 billion. The stock has run up 18.

 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 3. in SA

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين